Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

  1. Delimpasi, S.
  2. Mateos, M.V.
  3. Auner, H.W.
  4. Gavriatopoulou, M.
  5. Dimopoulos, M.A.
  6. Quach, H.
  7. Pylypenko, H.
  8. Hájek, R.
  9. Leleu, X.
  10. Dolai, T.K.
  11. Sinha, D.K.
  12. Venner, C.P.
  13. Benjamin, R.
  14. Garg, M.K.
  15. Doronin, V.
  16. Levy, Y.
  17. Moreau, P.
  18. Chai, Y.
  19. Arazy, M.
  20. Shah, J.
  21. Shacham, S.
  22. Kauffman, M.G.
  23. Richardson, P.G.
  24. Grosicki, S.
Revista:
American Journal of Hematology

ISSN: 1096-8652,  0361-8609

Any de publicació: 2022

Volum: 97

Número: 3

Pàgines: E83-E86

Tipus: Carta

DOI: 10.1002/AJH.26434 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus